Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).
Authors
Natalie Ngoi
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Natalie Ngoi , Emma L. Scholefield , Vamsi Parini , Richard S.P. Huang , Tyler Janovitz , Natalie Danziger , Mia Alyce Levy , Shubham Pant , Milind M. Javle , Jeffrey S. Ross , Jordi Rodon Ahnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.604
Abstract #
604
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.
First Author: Philippe E. Spiess
Poster
2016 ASCO Annual Meeting
Clinical Impact of extensive molecular profiling (EMP) in advanced cancer patients (pts) referred to early phase trial unit: The BIP (Bergonie Institute Profiling) Program.
First Author: Sophie Cousin
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff